Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test. FDA label
Also known as Tecentriq
Concurrent Atezolizumab · 1 trial · 1 indication
This measure is the number of subjects experiencing a dose-limiting toxicity. A dose-limiting toxicity is defined as an inability to complete radiation treatment within 30 days of the start of radiotherapy that is not deemed to be related to disease progression; OR an unacceptable toxicity within one year of treatment (Grade 4+ toxicity) that is probably or definitely related to radiation treatment as determined by the treating physician or a death within one year of treatment that is probably or definitely related to treatment.
This measure is the number of subjects experiencing a dose-limiting toxicity. A dose-limiting toxicity is defined as an inability to complete radiation treatment within 30 days of the start of radiotherapy that is not deemed to be related to disease progression; OR an unacceptable toxicity within one year of treatment (Grade 4+ toxicity) that is probably or definitely related to radiation treatment as determined by the treating physician or a death within one year of treatment that is probably or definitely related to treatment.
This measure is the number of subjects experiencing a dose-limiting toxicity. A dose-limiting toxicity is defined as an inability to complete radiation treatment within 30 days of the start of radiotherapy that is not deemed to be related to disease progression; OR an unacceptable toxicity within one year of treatment (Grade 4+ toxicity) that is probably or definitely related to radiation treatment as determined by the treating physician or a death within one year of treatment that is probably or definitely related to treatment.
This measure is the number of subjects experiencing a dose-limiting toxicity. A dose-limiting toxicity is defined as an inability to complete radiation treatment within 30 days of the start of radiotherapy that is not deemed to be related to disease progression; OR an unacceptable toxicity within one year of treatment (Grade 4+ toxicity) that is probably or definitely related to radiation treatment as determined by the treating physician or a death within one year of treatment that is probably or definitely related to treatment.
This measure is the highest radiation dose at which there is a 30% or more rate of dose-limiting toxicity up to 12 months after completion of radiation treatment using the TITE-CRM design.
| Arm | Type | Description |
|---|---|---|
| 50 Gray (Gy) Radiation Therapy with Concurrent Atezolizumab | EXPERIMENTAL | 50 Gy of ionizing radiation therapy will be administered in 15 fractions. |
| 50 Gray (Gy) Radiation Therapy | EXPERIMENTAL | 50 Gy of ionizing radiation therapy will be administered in 15 fractions. |
| 55 Gray (Gy) Radiation Therapy | EXPERIMENTAL | 55 Gy of ionizing radiation therapy will be administered in 15 fractions. |
| 60 Gray (Gy) Radiation Therapy | EXPERIMENTAL | 60 Gy of ionizing radiation therapy will be administered in 15 fractions. |
| Name | Type | Description |
|---|---|---|
| 50 Gy Radiation Therapy | RADIATION | Ionizing radiation |
| 55 Gy Radiation Therapy | RADIATION | Ionizing radiation |
| 60 Gy Radiation Therapy | RADIATION | Ionizing radiation |
| Concurrent Atezolizumab | DRUG | Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 4 weeks following the initiation of radiation treatment up to 1 year from radiation fraction 1. |
| Adjuvant Atezolizumab | DRUG | Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 28 days following the initiation of radiation treatment up to 1 year. |
Inclusion Criteria: * Age ≥18 years * Diagnosis of T3-T4 N0-N3 M0 or T0-T4 N1-N3 M0 squamous cell carcinoma of the head and neck squamous cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, or carcinoma of unknown head/neck primary) based on American Joint Committee on Cancer guidel...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, IMGN632, ABBV-744 |
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Luspatercept, BMS-986158, Fedratinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics Inc | KPTIQ | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Axatilimab, Ruxolitinib, INCB160058, INCB057643, INCA033989 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Revumenib |
Concurrent Atezolizumab is an investigational monoclonal antibody being studied in oncology. It is being developed by Roche Holding AG under the ticker RHHBY. It has been evaluated in a Phase 1 clinical trial in patients with head and neck neoplasm, where it was given alongside dose-escalated hypofractionated adaptive radiotherapy.
Concurrent Atezolizumab has been studied in head and neck neoplasm as part of a treatment regimen combined with dose-escalated hypofractionated adaptive radiotherapy. The Phase 1 trial enrolled 18 adult participants of any sex in the United States. It is an investigational agent and is not established as an approved therapy for this condition.
Concurrent Atezolizumab is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor associated with the clinical development of this monoclonal antibody in oncology, including the Phase 1 study conducted in patients with head and neck neoplasm.
Concurrent Atezolizumab is in Phase 1 development. The single registered trial, NCT04477759, is a completed Phase 1 study with 18 enrolled participants. The program is investigational and remains in clinical development, with no active trials currently listed for this asset.
Concurrent Atezolizumab has been evaluated in one clinical trial, NCT04477759, titled Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer. This completed Phase 1 study enrolled 18 adults in the United States and used a controlled design without randomization or double blinding.